Came back after an hour's workout on my treadmill. Of course, anyone has a right to his/her own views and so do you. My view that it is an accurate indirect statement is based on various factors:
1. The blended data in the 2018 paper by LL et al shows positive results. It is the opinion of many experts (I will name some in Point #3) on this MB that the data can only get better in 2020.
2. I have attended the talks by LL and the UCLA team in the last two months and posted their positive comments about DCVax-L on this MB.
3. It is the unanimous opinion of the best scientific and analytical posters here (Flipper, Senti, Lykiri, Meirluc, and Doc_logic) that the Phase III trial is a success. They have a combined experience of approximately 23 years among them with analyzing the DCVax-L trial.
Market Data 
Markets 
